The U.S. Food and Drug Administration (FDA) approved a supplemental application for Leqvio (inclisiran) on February 12, 2026. This approval pertains to an efficacy supplement, indicating an update or expansion related to the drug's demonstrated effectiveness.
Background
This supplemental approval for Leqvio (inclisiran) specifically addresses efficacy, which typically involves new data supporting an expanded indication, a new patient population, or an update to the drug's effectiveness profile. Such applications are filed when a manufacturer seeks to modify an existing approval based on new clinical trial data or post-market surveillance. Leqvio is sponsored by NOVARTIS.
What this means
The FDA's approval of a supplemental efficacy application for Leqvio (inclisiran) suggests that new data has been reviewed and accepted, potentially leading to an expanded label. This could mean the drug is now approved for a broader patient population, a new indication, or that its efficacy profile has been further substantiated, offering new treatment options or improved guidance for existing ones. Clinicians should consult the updated prescribing information for the specific details of this supplemental approval to understand its implications for patient care and to ensure appropriate patient selection and monitoring. This type of approval reflects ongoing research and development to optimize therapeutic benefits.
Source
This information was sourced from the U.S. Food and Drug Administration (FDA) website, specifically from an overview of application NDA214012. The supplemental application, identified as S-17, was approved on February 12, 2026, and is available on accessdata.fda.gov.